Psychotropic medication use among adolescents and young adults with an autism spectrum disorder: Parent views about medication use and health care services

Johanna K. Lake, Ph.D.¹,²
Vanessa Vogan, M.A.¹,³
Amanda Sawyer, M.D.¹,²
Jonathan A. Weiss, Ph.D., C. Psych.⁴
Yona Lunsky, Ph.D., C. Psych.¹,²

¹ Centre for Addiction and Mental Health
² Department of Psychiatry, University of Toronto
³ Department of Applied Psychology and Human Development, Ontario Institute for Studies in Education
⁴ Department of Psychology, York University

*Corresponding author: Johanna K. Lake, Dual Diagnosis Service, Centre for Addiction and Mental Health, 1001 Queen St. W., Unit 4-3, Toronto, ON M5V 2B4 Canada; phone: (416) 535-8501 x37823, fax: (416) 603-9120; johanna.lake@camh.ca

Funding Sources: The Canadian Institutes of Health Research (funding reference number 102677) and the Centre for Addiction and Mental Health Postdoctoral Fellowship Award.

Final publication is available from Mary Ann Liebert, Inc., publishers http://online.liebertpub.com/doi/10.1089/cap.2014.0106
Abstract

**Objectives:** Psychotropic medications are frequently used to treat mental health and behavioral issues in adolescents and adults with an autism spectrum disorder (ASD). Although parents of individuals with ASD frequently take on medication management for their child, there is limited literature on parent *perspectives* of their child’s medication use or their views about the health care services they receive, particularly in adulthood. The current study examined and compared parents of adolescents and of young adults with ASD on their child’s psychotropic medication use and their views about health care services. **Methods:** One hundred parents of adolescents and young adults with ASD (ages 12-30 years) completed an online survey about their experience with their child’s health care services and medication use. **Results:** Parents of young adults were less likely to use non-pharmacological services before using a psychotropic medication compared to parents of adolescents. Parents of young adults were also less likely to believe their prescribing health care provider had adequate expertise in ASD and were less satisfied with how their prescriber monitored their child’s medication use. **Conclusion:** Findings highlight the need to build capacity among health care providers supporting individuals with ASD as they transition into adulthood. There is also a need for improved medication monitoring and increased awareness of the different mental health challenges individuals with ASD encounter as they age.

Key words: autism spectrum disorder; psychotropic medication; young adults; adolescents; health care provider, parent experiences
Psychotropic medication use among adolescents and young adults with an autism spectrum disorder: Parent views about medication use and health care services

Individuals with an autism spectrum disorder (ASD) are frequently prescribed psychotropic medications (Coury et al. 2012; Hsia et al. 2013; Logan et al. 2012; Memari et al. 2012; Rosenberg et al. 2010; Schubart et al. 2013; Spencer et al. 2013), with over three quarters taking psychotropic drugs by the time they reach adulthood (Esbensen et al. 2009; Spencer et al. 2013). Despite their widespread use, literature on psychotropic medication use in adolescents and young adults with ASD remains limited. Of the few studies conducted to date, most have examined medication rates or associated demographic and clinical variables (Coury et al. 2012; Esbensen et al. 2009; Lake et al. 2012; Lake, Weiss, Dergal and Lunsky, in press; Spencer et al. 2013), but not the experience of using medication, such as knowledge about or satisfaction with medication monitoring.

Associated mental health issues, and deficits in social, communicative and cognitive functioning often impede individuals with ASD from managing their own health care (Bruder et al. 2012). Consequently, the responsibility for coordinating and managing health care and service provision for their adolescent or adult child, including medication use, frequently falls on parents or other caregivers (Bruder et al. 2012; Carbone et al. 2010; Howlin et al. 2004; Levy and Perry 2011). Despite this, the little we know about parent perspectives regarding their child’s health care and medication use comes from studies of children. Generally, this literature suggests that parents are dissatisfied with the health care services that their child receives (Carbone et al. 2010;
We know even less about parent perspectives as individuals with ASD enter adulthood, when the needs of patients and families may change (Graetz 2010). This transition can be particularly challenging for individuals with ASD, not only in terms of physiological changes, but also because of possible changes to residence, education, and employment. Additionally, young adults may encounter significant changes in service eligibility or accessibility, and some adults may no longer be eligible or have access to funded non-pharmacological services or supports. For example, adolescents access services through children’s services and the school system, whereas young adults receive services within the adult system. Further, young adults must move from the pediatric to the adult health care system, where access to health care professionals and trainees who have the capacity and expertise to care for individuals with ASD is sparse (Bruder et al. 2012; Cheak-Zamora et al. 2013; Marrus et al. 2014). Lastly, medication efficacy, tolerability, and the reason(s) for prescribing medication or the individual’s psychiatric presentation, may also differ between the two groups. For these reasons, there is a clear need to better understand the unique experience of medication use among transitioning youth with ASD, and how these experiences differ from younger adolescents.

In the only study to examine parent perspectives on psychotropic medication use among adolescents and adults with ASD, we identified a number of key concerns related to medication use and prescribing health care providers (Lake, Milovanov, Sawyer and Lunsky, in press). Specifically, our qualitative study found that parents voiced concerns about side effects and medication efficacy, as well as concerns related to the low
frequency and lack of standardization of medication monitoring. Parents also commented on the need for prescribers with expertise in ASD, and for a better integrated system with enhanced communication among health care professionals and an interdisciplinary approach to treatment. While findings represent an important first step on this topic, quantitative research is needed to follow up this qualitative, exploratory study more systematically, and with a larger cohort of individuals (Goering and Streiner 1996).

The current study adds to the limited literature on parent perspectives of psychotropic medication use among adolescents and young adults with ASD, and expands previous qualitative work using a larger, more diverse sample, divided into two subgroups: one of adolescents and the other of young adults with ASD. Our specific study objectives include: 1) to describe and compare the number and type of medications prescribed in the two groups; and 2) to describe and compare parent perspectives of their adolescent or young adult child’s medication use (i.e., reason for medication prescription, comfort with medication use, medication side effects, and medication efficacy) and parent perspectives regarding health care services received (i.e., expertise issues, use of previous services prior to medication use, satisfaction with medication monitoring, availability and accessibility of non-pharmacological services).

Methods

The analyses reported here are part of a larger project examining health service utilization patterns among individuals with ASD. Participants were recruited across Ontario through flyers, websites, and announcements targeted at relevant support groups, recreational programs, community agencies and schools. Efforts were made to reach families living in all regions of the province, including remote and rural settings where
individuals may be marginalized economically or geographically. Parents from this larger project who noted that their child had been prescribed psychotropic medication \((n=363)\), were invited to participate in a follow-up survey. Parents were deemed eligible if they had a child with ASD between 12 and 30 years of age who was currently prescribed at least one psychotropic medication. Of the 363 parents contacted, 113 parents completed the follow-up survey. Two of these parents had a child under the age of 12, and 11 did not have a child who met the recommended Social Communication Questionnaire (SCQ; Rutter et al. 2003) research cut-off score of \(\geq12\) (Brooks and Benson 2013). As a result, 13 parents were excluded from our analysis resulting in a final sample size of 100 participants. Respondents were not paid to complete the survey, and participants understood that their responses would be linked to their longitudinal data. Individuals with ASD were classified as adolescents if they were between 12 and 18 years of age, and young adults if they were between 19 and 30 years.

**Participants**

Adolescents with ASD \((n=55)\) had a mean age of 15.45 years \((SD=1.68)\), and young adults \((n=45)\) a mean age of 22.2 years \((SD=3.17)\). Parents had a mean age of 45.74 years \((SD=6.13)\) and 52.3 years \((SD=4.78)\), respectively. No significant differences were identified among adolescents and young adults in terms mean SCQ score. Over three-quarters of adolescents and young adults with ASD were male, most were Caucasian, and almost all were living with family (Table 1). No significant group differences were observed in terms of gender ratios, ID status, rates of medical or psychiatric comorbidity, residence, or ethnicity. Compared to young adults, more
adolescents were engaged in structured daytime activities, likely because they were still attending mandatory schooling.

**Materials/Procedure**

Background and socio-demographic characteristics, along with information about the child’s medication use and experience with prescribing health care providers, were all obtained via an online survey. This included information on medication and side effects; parent comfort regarding their child’s medication use; satisfaction with prescriber medication monitoring; and access to and satisfaction with prescribing health care providers. Survey development was informed by findings obtained from a focus group of seven parents with an adolescent or adult child prescribed psychotropic medication (see “Author” under review, for further detail on the focus group). During this previously conducted focus group, parents discussed their experience with medication use and interactions with prescribers. Emergent themes from the group helped frame the final version of the current survey and also formed the basis of subsequent analyses in the present study. Prior to launching the survey, measures were piloted among participants of the focus group and adapted accordingly. The final version of the survey took approximately 20 minutes to complete and could be completed online or by phone. All parents provided informed written consent after being provided with a detailed description of the study. This study received ethics approval through the relevant institution’s institutional review board.

**Study Variables**

*Demographic and Clinical*
The following demographic and clinical variables were examined at the descriptive level: gender, intellectual disability status (ID), ethnicity, residence, structured daily activity, medical comorbidity, psychiatric comorbidity, body mass index (BMI) and ASD severity. Individuals were classified as having ID if parents indicated that their child had a diagnosis of mild, moderate, severe, or profound ID. ASD symptom severity was measured using the SCQ (Rutter et al. 2003), a validated parent-report instrument of autism severity. The SCQ consists of 40 items, based on the Autism Diagnostic Interview-Revised (ADI-R), which has demonstrated validity (Chandler et al. 2007; Howlin and Karpf 2004; Witwer and Lecavalier 2007) and good internal consistency, with Chronbach alphas ranging from 0.81-0.93 (Naglieri and Chambers 2009). Information on BMI was obtained through parent reported child height, weight, and pant size/waist circumference.

**Medication and Side Effects**

Medications were categorized into the following 11 medication classes for standard use: a) Psychotropic medications: antidepressants, anxiolytics, atypical antipsychotics, typical antipsychotics, stimulants, mood stabilizers, and b) Non-psychotropic medications: anticonvulsants, antihypertensives, medications for gastrointestinal issues, medications for sleep issues (e.g., melatonin, zoplicone), and other non-psychotropic medications. Only antihypertensive medications which had evidence for the treatment of hyperactivity, inattention, or impulsivity, such as clonidine or guanfacine, (Arnsten et al. 2007; Posey et al. 2004) were categorized as psychotropic medication, as was done by others (Aman et al. 2003; Lake et al., in press; Langworthy-Lam et al. 2002; Logan et al. 2012). Similarly, the distinction between mood stabilizers
and anticonvulsants was made by classifying medications (e.g., valproate and carbamazepine) as mood stabilizers for all individuals who did not have a diagnosis of seizure disorder, as has been done previously (Esbensen et al. 2009; Lake et al. 2012; Spencer et al. 2013). Parents were also asked if their child had experienced side effects as a result of medication use (yes, no, don’t know), what side effects their child had experienced (open-ended), and what effect, they felt, medication (s) had on their child’s psychological wellbeing (good or mostly good, neutral, bad or mostly bad). Medication side effects were then classified into the following categories: metabolic (e.g., weight gain, increased appetite, increased blood pressure, increased blood sugar), cardiac (e.g., increased heart rate), movement (e.g., muscle stiffness, tics, involuntary movements), fatigue/sleep (e.g., lethargy, somnolence, sedation, nightmares), general neurological change (e.g., headaches, dizziness, disorientation, slowed down, subdued), behaviour change (e.g., mania, fixed thoughts, aggression, anxiety, irritable, depression), serious neurological events (e.g., seizure), endocrine (e.g., lactation, breast growth), dermatological (e.g., acne), gastrointestinal (e.g., constipation, loose bowels, nausea), hematological (e.g., nose bleed, low iron), temperature dysregulation (e.g., heat sensitivity, fever), weight loss, thirst, sexual (e.g., sexual dysfunction), and genitourinary (e.g., urinary retention). Classifications were based on literature on medication side effects (AHFS, 2014; Matson et al., 1998), and side effects were independently verified and coded by two authors (VV, AS).

**Parent Views about Medication**

We examined the following variables regarding parents’ views about medication: reason(s) for medication prescription (targeted symptoms) and parental ratings of their
comfort with medication(s) (comfortable, neutral, uncomfortable). Targeted symptoms were classified into the following four behavior or mental health categories based on parent-report of why their child was prescribed medication: externalizing behaviours (e.g., repetitive, aggressive, oppositional or self-injurious behavior, ADHD symptoms), internalizing problems (e.g., anxiety, depression, bipolar), social issues (e.g., social appropriateness, eye contact, understanding emotional cues), and psychotic disorder (e.g., schizophrenia, schizoaffective disorder).

**Parent Views about Health Care Services**

We examined the following variables related to parents’ views about health care services: prescriber expertise in ASD (yes/no), use of previous supports or services prior to medication use (yes/no), satisfaction with how medication is monitored by prescribing health care provider (satisfied, neutral or dissatisfied), and role of non-pharmacological services (health care provider/school/service suggested medication, no access/availability of non-pharmacological services, non-pharmacological services not/partially working).

**Data Analysis**

Descriptive statistics were used to describe demographic and clinical information for the sample (numbers and percentages for count data and means and standard deviations for continuous variables). Bivariate analyses were conducted to compare the views of parents of adolescents versus those of young adults with ASD in terms of their child’s medication use, the type and number of medications their child was prescribed, and their views about health care services. Statistical analyses were conducted using SPSS version 20.0.

**Results**
Medication and Side Effects

As shown in Table 2, antipsychotic medications were the most commonly prescribed medication among the total sample (56%), and among adolescents specifically (54.5%). Young adults (68.9%) were significantly more likely to use antidepressant medications than adolescents (41.8%), $\chi^2(1)=7.3, p=0.007$, and adolescents (40.0%) were more likely to use stimulants than young adults (15.6%), $\chi^2(1)=7.18, p=0.007$. Parents of adolescents (85.5%) were significantly more likely to have a child prescribed psychotropic medication for externalizing behaviours compared to parents of young adults (61.4%), $\chi^2(1)=7.52, p=0.006$. Forty percent of young adults used non-psychotropic medications in addition to a psychotropic medication, while only 25% of adolescents used these medications. On average, young adults were prescribed more psychotropic and non-psychotropic medications ($M = 2.27$) than adolescents ($M = 1.91$), and almost half of all adolescents (43.7%) and young adults (48.9%) were taking two or more psychotropic medications concurrently.

Parents of adolescents (70.9%) were more likely to report that their child had experienced side effects as a result of psychotropic medication use compared to parents of young adults (48.8%), $\chi^2(2)=7.27, p=0.003$ (Table 4). Specifically, parents of adolescents were more likely to report that their child had experienced weight loss as a side effect of medication use, and although not statistically significant, metabolic side effects were also more common among adolescents (30.9%) than young adults (19.5%) (Table 3). Almost half of the total sample fell in either the overweight (24.4%) or obese (20.0%) BMI category, and nearly one-quarter of parents of young adults reported that they did not know if their child had experienced medication side effects, compared to
only 6% of adolescents. Most parents in both groups (adolescents=77.4%; young adults=80.0%) believed medication had a good/mostly good effect on their child’s behavior or mental health, and approximately one third of parents of both adolescents and young adults reported that they were comfortable with the medication(s) their child was taking.

**Parent Views about Health care Services**

Most parents of adolescents (80.0%) and young adults (84.4%) indicated that their child’s prescriber monitored their child’s medications 2-3 times a year or less. Parents of young adults were less satisfied with how their prescriber monitored their child’s medication, $\chi^2(1)=4.48, p=0.03$, and were less likely to feel their prescriber had adequate expertise in ASD, $\chi^2(1)=5.14, p=0.02$. Compared to parents of adolescents, parents of young adults were also less likely to use previous supports or services before trying medication ($p=0.05$). Finally, almost one-third of adolescents and one-quarter of young adults reported that non-pharmacological services or supports were not or only partially working for behavior or mental health problems (Table 5).

**Discussion**

This is the first study to examine parent perspectives of their child’s psychotropic medication use by comparing the experiences of parents of adolescents to parents of young adults transitioning out of the pediatric health care system. Findings highlight key differences between the experiences of adolescents and their parents and the experiences young adults and their parents. The two groups differed in terms of their medication profiles, medication side effects, satisfaction with care from prescribers, and relative use
of other health care services. Differences point to target areas for intervention and opportunities for intervention with youth and their families prior to adulthood.

Consistent with previous studies (Aman et al. 2005; Mandell et al. 2008), the most frequent reason for a medication prescription among adolescents was externalizing behaviours, while internalizing problems were more common among young adults. Medication profiles reflected these differences with stimulant medications more frequently prescribed among adolescents (adolescents=40%; young adults=16%), and antidepressants among young adults (adolescents=42% young adults=69%). Better evidence of the efficacy of antidepressant use in adults with ASD may in part explain this difference (Doyle & McDougle, 2012).

In terms of medication side effects, parents of adolescents were more likely to report that their child had experienced side effects compared to parents of young adults. This finding may reflect differences in the metabolism of specific medications in adolescents versus adults (Ginsberg et al. 2002), but it may also be that with chronic medication use, parents of young adults become less aware of medication side effects compared to parents of adolescents. Another possibility is that the greater number of side effects observed in adolescents is linked to higher stimulant use which is associated with more frequent reports of weight loss and movement abnormalities. In our study, nearly one quarter of parents of young adults reported that they did not know if their child was experiencing medication side effects. The mean number of medications for young adults (2.27) was higher than for adolescents (1.91) in the current study, perhaps making it difficult to discern side effects.

One of the most concerning side effects of medication use is weight gain. In the
current study, almost half of all young adults and adolescents were overweight or obese, a finding consistent with studies of young adults with ASD (Eaves and Ho 2008), but higher than what has been reported in studies of children with ASD (Zuckerman et al. 2014). This rate is also more than double the rate among the general adolescent population (Roberts et al. 2012). Similarly, almost one third of adolescents reported metabolic side effects, which is not surprising given that 84% were prescribed antipsychotic drugs. More specifically, 71% of these individuals were prescribed atypical antipsychotic medications (e.g., Risperidone, Olanzapine Aripiprazole, Paliperidone), all medications with known metabolic effects. While medication use is one contributor of obesity, there are a number of other factors that may also contribute, including restrictive eating patterns, motor impairments, cognitive impairments, and medical comorbidities, all common among individuals with ASD (Egan et al. 2013; Zuckerman et al. 2014). Alongside high rates of metabolic side effects, parents of adolescents were more likely to report weight loss or decreased appetite as a result of medication use, however this may be due to greater use of stimulants among adolescents. For these reasons, there is an even greater need for prescribers to monitor for metabolic side effects when prescribing psychotropic medications that have the potential to cause weight gain or loss among individuals with ASD.

In the current study, approximately 80% of individuals using medication had their medication monitored only two to three times a year or less, despite almost half of the sample taking two or more psychotropic medications concurrently. This finding is concerning in the context of recent guidelines for the primary care of persons with developmental disabilities which recommend medication monitoring every 3 months.
Guidelines developed by the National Institute for Health and Care Excellence (NICE; NICE 2012) suggest medication monitoring every two to three weeks during the initiation phase of a psychotropic medication prescription, but do not specify ongoing monitoring requirements. Canadian guidelines for the monitoring of antipsychotic medications recommend monitoring antipsychotic medications every three to six months, and more frequently in vulnerable populations, including individuals with ASD (Cohn and Semyak 2006; McCracken 2005). Individuals with ASD are more sensitive to medication side effects, adding to the need to carefully monitor medication use in this population (McCracken 2005). This may be linked to the finding that some parents were dissatisfied with how their child’s medications were monitored. Unfortunately, this problem may be compounded by challenges finding a prescribing health care provider who is comfortable or familiar prescribing and monitoring medications for individuals with ASD, especially in adulthood. Together, findings highlight the need for prescribers to monitor psychotropic and non-psychotropic medications, particularly as individuals with ASD age and may be at greater risk for comorbid conditions and the use of multiple medications.

Compared to parents of adolescents, parents of young adults with ASD were significantly less likely to believe their prescriber had adequate expertise in ASD and also felt less satisfied with how their prescriber monitored their child’s medication. This finding is particularly concerning given heightened rates of comorbid psychiatric (Doshi-Velez et al. 2014; Kohane et al. 2012) and medical problems (Bauman 2010; Doshi-Velez et al. 2014; Kohane et al. 2012) among adults with ASD. As individuals age the likelihood of developing a comorbid medical problem increases, and although our sample
of adults was relatively young, almost half of them were prescribed non-psychotropic medications in addition to a psychotropic medication prescription. Going forward it will be important to understand why young adults are prescribed non-psychotropic medications (e.g., to counteract effect of psychotropic drugs or for health issues), as well as how best to support the complex medical and psychiatric needs of this population.

Findings suggest that the pathway to medication use may be different for parents of young adults compared to adolescents. Not only did the medication profiles of adolescent and young adults with ASD differ, but so did their experiences with health care services. There are a number of possible explanations for these differences – results could be explained by a cohort effect where older parents simply have different experiences than younger parents. It could also be the case that when parents start their child on medication later in life, they are less likely to pursue other services and supports. Or it may be that parents of young adults experience greater difficulty finding and accessing services or supports for their adult child once they are no longer eligible for services funded through the educational or pediatric health care systems. Despite the fact that a number of evidence-based non-pharmacological practices for individuals with ASD exist, including intensive behavior intervention, positive behavior supports, and cognitive behavior therapy (Perry and Condillac 2003), medication may be the only readily available, accessible, and funded treatment option for many young adults. Other studies have shown that there may be barriers to accessing appropriate non-pharmacological services once individuals with ASD reach adulthood (Gerhardt & Lainer, 2011; Shattuck, Wagner, Narendorf, Sterzing & Hensley 2011; Shattuck et al., 2012). Regardless of age, it is important that all individuals with ASD follow guidelines which argue for access to
psychosocial interventions prior to medication use for the treatment of mental health
issues among individuals with ASD (NICE 2012; Sullivan et al. 2011).

The study is subject to a number of limitations. First, findings are based on parent
report data, and we did not have access to corroborating sources to validate diagnoses or
medications. However, only individuals with an SCQ score at or above the recommended
cutoff (≥12; Brooks and Benson 2013) were included in these analyses. It is possible that
some individuals in this study would not meet full DSM-V criteria for ASD; however,
previous studies suggest that parent-reported ASD diagnoses produce prevalence
estimates comparable to population-based studies using validated medical records or
diagnostic tools (CDC 2012, 2013; Kogan et al. 2008). While we recognize that our
sample may not be representative of all individuals with ASD, most individuals with
ASD tend to reside with their parents well into adulthood (Howlin and Moss 2012), thus
findings from parent report surveys have considerable value in understanding adolescents
and young adults with ASD. In addition, the authors did not have access to longitudinal
medication information. This information could help clarify, for example, the relationship
between satisfaction with medication monitoring and medication side effects, efficacy,
comfort, or prescriber expertise. Similarly, despite its constraints, a number of studies
have used similar survey-based methods to study this population (Blumberg et al. 2013;
Mazurek 2013; Mazurek et al. 2011; Montes and Halterman 2007) including the 2011-
2012 National Survey of Children’s Health (CDC 2013) and the 2011-2012 National
Health Interview Survey (CDC 2012).

Conclusions
In the current study, young adults with ASD accessed fewer non-pharmacological supports before trying a medication prescription, and parents felt their prescribers had less expertise in ASD. This may suggest that young adults face particular challenges accessing services and supports once they age out of the pediatric system—a concerning finding given heightened rates of comorbid psychiatric disorders and medication use in adulthood. Given high rates of medication use observed in this population, an important next step will be to identify ways to support and train health care providers in obtaining the expertise to effectively care for these individuals. This will also involve ensuring that medications are prescribed and monitored according to best practice guidelines.
Clinical Significance: This is the first study of adolescents and young adults with ASD to examine parent perspectives of their child’s psychotropic medication use and their views about health care services. Findings identified that compared to parents of adolescents; parents of young adults were less likely to access non-pharmacological services and supports prior to initiating a psychotropic medication. Parents of young adults were also less likely to feel their prescriber had expertise in ASD, and were less satisfied with how their child’s medications were monitored. This may suggest there are limited non-pharmacological services for young adults with ASD, and also highlight the need to build capacity among clinicians providing care to young adults where there are fewer mental health professionals who feel equipped to provide care to this population.

Disclosures: None for any author

Acknowledgments The authors thank the Canadian Institutes of Health Research (funding reference number 102677) and the Centre for Addiction and Mental Health Postdoctoral Fellowship Award for funding this research study.
References


Table 1. Descriptive statistics of sample (n=100).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Adolescents (12-18) (n=55) %</th>
<th>Young Adults (19-30) (n=45) %</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (male)</td>
<td>83.6</td>
<td>75.6</td>
<td>χ²(1) = 1.01, p = 0.32</td>
</tr>
<tr>
<td>Intellectual disability</td>
<td>54.0</td>
<td>50.0</td>
<td>χ²(1) = 0.15, p = 0.70</td>
</tr>
<tr>
<td>Caucasian</td>
<td>87.3</td>
<td>82.2</td>
<td>χ²(1) = 0.50, p = 0.48</td>
</tr>
<tr>
<td>Living with family</td>
<td>100.0</td>
<td>92.5</td>
<td>χ²(1) = 4.03, p = 0.05</td>
</tr>
<tr>
<td>Structured activity</td>
<td>98.2</td>
<td>75.6</td>
<td>χ²(1) = 12.00, p = 0.001***</td>
</tr>
<tr>
<td>Medical comorbidity</td>
<td>33.0</td>
<td>33.0</td>
<td>χ²(1) = 0.004, p = 0.95</td>
</tr>
<tr>
<td>Psychiatric comorbidity</td>
<td>63.3</td>
<td>73.6</td>
<td>χ²(1) = 1.07, p = 0.30</td>
</tr>
</tbody>
</table>

*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
Table 2. Medication use associated with adolescents and young adults with ASD (n=100).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Adolescents (n=55)</th>
<th>Young Adults (n=45)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>Mean (SD)</td>
<td>%</td>
</tr>
<tr>
<td>Medication drug classes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antipsychotic</td>
<td>54.5</td>
<td>57.8</td>
<td></td>
</tr>
<tr>
<td>Anxiolytic</td>
<td>7.3</td>
<td>6.7</td>
<td></td>
</tr>
<tr>
<td>Antidepressant</td>
<td>41.8</td>
<td>68.9</td>
<td></td>
</tr>
<tr>
<td>Mood Stabilizer</td>
<td>0</td>
<td>4.4</td>
<td></td>
</tr>
<tr>
<td>Stimulant</td>
<td>40.0</td>
<td>15.6</td>
<td></td>
</tr>
<tr>
<td>Non-psychotropic medication</td>
<td>25.5</td>
<td>40.0</td>
<td></td>
</tr>
<tr>
<td>Number of medications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean number of total medications</td>
<td>1.91 (1.08)</td>
<td>2.27 (1.53)</td>
<td></td>
</tr>
<tr>
<td>2 concurrent psychotropic</td>
<td>43.6</td>
<td>48.9</td>
<td></td>
</tr>
</tbody>
</table>

*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
Table 3. Type and number of medication side effects associated with adolescents and young adults with ASD ($n=100$).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Adolescents ($n=55$)</th>
<th>Young Adults ($n=45$)</th>
<th>$p$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>Rank</td>
<td>%</td>
</tr>
</tbody>
</table>
| Medication side effects | | | | | \(\chi^2(2)=7.27, p=.003^{**} \)
| Yes | 70.9 | 48.8 | | |
| No | 23.6 | 29.3 | | |
| Don’t know | 5.5 | 22.0 | | |
| Top 5 most commonly reported medication side effects | | | | |
| Metabolic | 30.9 | 1 | 19.5 | 2 |
| Fatigue/sleep | 23.6 | 2 | 22.0 | 1 |
| Weight loss | 16.4 | 3 | 2.4 | - |
| Behaviour change | 16.4 | 3 | 12.2 | 4 |
| Movement | 14.5 | 4 | 7.3 | 5 |
| General neurological change | 9.1 | 5 | 17.1 | 3 |
| Gastrointestinal | 9.1 | 5 | 7.3 | 5 |

* \(p \leq 0.05 \), ** \(p \leq 0.01 \), *** \(p \leq 0.001 \)
Table 4. Parent perspectives on medication use among adolescents and young adults with ASD (n=100).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Adolescents (n=55)</th>
<th>Young Adults (n=45)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td><strong>Reason for medication prescription</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Externalizing behaviours</td>
<td>85.5</td>
<td>61.4</td>
<td>$\chi^2(1)=7.52, p=0.006^{**}$</td>
</tr>
<tr>
<td>Internalizing problems</td>
<td>70.9</td>
<td>84.1</td>
<td>$\chi^2(1)=2.38, p=0.12$</td>
</tr>
<tr>
<td>Social issues</td>
<td>12.7</td>
<td>11.6</td>
<td>$\chi^2(1)=0.03, p=0.87$</td>
</tr>
<tr>
<td>Psychotic disorder</td>
<td>5.5</td>
<td>9.1</td>
<td>$\chi^2(1)=0.49, p=0.48$</td>
</tr>
<tr>
<td><strong>Comfort with medication use</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comfortable</td>
<td>36.4</td>
<td>33.3</td>
<td></td>
</tr>
<tr>
<td>Neutral</td>
<td>49.1</td>
<td>40.0</td>
<td>$\chi^2(3)=2.49, p=0.48$</td>
</tr>
<tr>
<td>Uncomfortable</td>
<td>3.6</td>
<td>8.9</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>10.9</td>
<td>17.8</td>
<td></td>
</tr>
<tr>
<td><strong>Medication efficacy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good or mostly good</td>
<td>77.4</td>
<td>80.0</td>
<td>$\chi^2(2)=0.44, p=0.80$</td>
</tr>
<tr>
<td>Neutral</td>
<td>17.0</td>
<td>12.5</td>
<td></td>
</tr>
<tr>
<td>Bad or mostly bad</td>
<td>5.7</td>
<td>7.5</td>
<td></td>
</tr>
</tbody>
</table>

*p $\leq 0.05$, **p $\leq 0.01$, ***p $\leq 0.001$
Table 5. Parent views about health care services associated with adolescents and young adults with ASD (n=100).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Adolescents (n=55)</th>
<th>Young Adults (n=45)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Views about prescribers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prescriber expertise in ASD</td>
<td></td>
<td></td>
<td>(\chi^2(1)=5.14, p=0.02^*)</td>
</tr>
<tr>
<td>Yes</td>
<td>69.1</td>
<td>43.9</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>30.9</td>
<td>56.1</td>
<td></td>
</tr>
<tr>
<td>Satisfaction with prescriber medication monitoring</td>
<td></td>
<td></td>
<td>(\chi^2(1)=4.48, p=0.03^*)</td>
</tr>
<tr>
<td>Satisfied</td>
<td>53.7</td>
<td>38.1</td>
<td></td>
</tr>
<tr>
<td>Neutral or Dissatisfied</td>
<td>46.3</td>
<td>67.9</td>
<td></td>
</tr>
<tr>
<td><strong>Views about services</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of non-pharmacological services prior to initiating medication use</td>
<td></td>
<td></td>
<td>(\chi^2(1)=3.88, p=0.05^*)</td>
</tr>
<tr>
<td>Yes</td>
<td>81.8</td>
<td>64.4</td>
<td></td>
</tr>
<tr>
<td>Role of non-pharmacological services</td>
<td></td>
<td></td>
<td>(\chi^2(3)=3.40, p=0.33)</td>
</tr>
<tr>
<td>No access to or availability of non-pharmacological services</td>
<td>1.9</td>
<td>9.8</td>
<td></td>
</tr>
<tr>
<td>Non-pharmacological supports not or only partially working</td>
<td>32.7</td>
<td>24.4</td>
<td></td>
</tr>
<tr>
<td>Healthcare provider, school, or other service suggested medication</td>
<td>51.9</td>
<td>48.8</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>13.5</td>
<td>17.1</td>
<td></td>
</tr>
</tbody>
</table>

*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001